RT Journal Article SR Electronic T1 94 Risk factors for lymph node metastasis of ovarian, fallopian tube and primary peritoneal cancer in hereditary breast and ovarian cancer syndrome JF International Journal of Gynecologic Cancer JO Int J Gynecol Cancer FD BMJ Publishing Group Ltd SP A55 OP A55 DO 10.1136/ijgc-2020-ESGO.99 VO 30 IS Suppl 4 A1 Mitamura, Takashi A1 Sekine, Masayuki A1 Arai, Masami A1 Yokoyama, Shiro A1 Yamashita, Hiroko A1 Watari, Hidemichi A1 Yabe, Ichiro A1 Nomura, Hiroyuki A1 Enomoto, Takayuki A1 Nakamura, Seigo YR 2020 UL http://ijgc.bmj.com/content/30/Suppl_4/A55.1.abstract AB Introduction/Background To establish an individualized surgical strategy for ovarian cancer in patients with the germline BRCA1 and BRCA2 pathogenic variants (BRCA1+ and BRCA2+), we investigated the clinicopathological characteristics that are involved in the increased risk of lymph node metastasis (LNM).Methodology We retrospectively reviewed the data of 509 Japanese women who underwent BRCA1 and BRCA2 genetic testing and were registered in the database of the Japanese HBOC Consortium.Results BRCA1+ and BRCA2+ were found in 232 (45.6%) of patients in our database, while other patients had no pathogenic variant (BRCA-). The prevalence of LNM was not markedly different between BRCA- (19.5%), BRCA1+ (18.4%) and BRCA2+ (26.2%). Multivariate analysis revealed an absence of a family history of ovarian cancer as an independent predictor for an increased risk of LNM in BRCA1+, and the prevalence of LNM was 11.7% and 42.0% in the groups with and without a family history of ovarian cancer, respectively. This subgroup without a family history of ovarian cancer did not show any correlation with a particular variant of BRCA1.Conclusion This study suggested that the existence of a subgroup in which the absence of a family history of ovarian cancer was an independent predictor for an increased risk of lymph node metastasis and certain genetic factors related to the penetrance of hereditary breast and ovarian cancer syndrome might alter the frequency of LNM in BRCA1+ ovarian cancer. We will need to investigate whether or not the same surgical strategy for lymphadenectomy as BRCA- is suitable for this BRCA1+ subgroup.Disclosures There are no conflict of interest disclosures from any authors.